GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort CardioFlow Medtech Corp (HKSE:02160) » Definitions » ROE %

MicroPort CardioFlow Medtech (HKSE:02160) ROE % : -23.40% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is MicroPort CardioFlow Medtech ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. MicroPort CardioFlow Medtech's annualized net income for the quarter that ended in Dec. 2023 was HK$-639.1 Mil. MicroPort CardioFlow Medtech's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was HK$2,731.0 Mil. Therefore, MicroPort CardioFlow Medtech's annualized ROE % for the quarter that ended in Dec. 2023 was -23.40%.

The historical rank and industry rank for MicroPort CardioFlow Medtech's ROE % or its related term are showing as below:

HKSE:02160' s ROE % Range Over the Past 10 Years
Min: -70.34   Med: -18.33   Max: -13.27
Current: -18.12

During the past 6 years, MicroPort CardioFlow Medtech's highest ROE % was -13.27%. The lowest was -70.34%. And the median was -18.33%.

HKSE:02160's ROE % is ranked worse than
64.89% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: -0.54 vs HKSE:02160: -18.12

MicroPort CardioFlow Medtech ROE % Historical Data

The historical data trend for MicroPort CardioFlow Medtech's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort CardioFlow Medtech ROE % Chart

MicroPort CardioFlow Medtech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -70.34 - -13.27 -14.78 -18.33

MicroPort CardioFlow Medtech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.16 -7.86 -22.52 -13.12 -23.40

Competitive Comparison of MicroPort CardioFlow Medtech's ROE %

For the Medical Devices subindustry, MicroPort CardioFlow Medtech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MicroPort CardioFlow Medtech's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's ROE % distribution charts can be found below:

* The bar in red indicates where MicroPort CardioFlow Medtech's ROE % falls into.



MicroPort CardioFlow Medtech ROE % Calculation

MicroPort CardioFlow Medtech's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-515.754/( (3075.114+2553.824)/ 2 )
=-515.754/2814.469
=-18.33 %

MicroPort CardioFlow Medtech's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-639.056/( (2908.224+2553.824)/ 2 )
=-639.056/2731.024
=-23.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


MicroPort CardioFlow Medtech  (HKSE:02160) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-639.056/2731.024
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-639.056 / 349.512)*(349.512 / 2995.651)*(2995.651 / 2731.024)
=Net Margin %*Asset Turnover*Equity Multiplier
=-182.84 %*0.1167*1.0969
=ROA %*Equity Multiplier
=-21.34 %*1.0969
=-23.40 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-639.056/2731.024
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-639.056 / -629.914) * (-629.914 / -450.076) * (-450.076 / 349.512) * (349.512 / 2995.651) * (2995.651 / 2731.024)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0145 * 1.3996 * -128.77 % * 0.1167 * 1.0969
=-23.40 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


MicroPort CardioFlow Medtech ROE % Related Terms

Thank you for viewing the detailed overview of MicroPort CardioFlow Medtech's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


MicroPort CardioFlow Medtech (HKSE:02160) Business Description

Traded in Other Exchanges
Address
No. 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, CHN, 201203
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of three products VitaFlow, VitaFlow Liberty, and Alwide Plus, and various TAVI products, TMV products, TTV products, surgical valve products, and procedural accessories. Geographically, it derives a majority of its revenue from China.
Executives
China Renaissance Holdings Limited 2201 Interest of corporation controlled by you
Hua Jie Tian Jin Yi Liao Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Hua Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Tian Jin Hua Jie Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hua Qing Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Microport Scientific Corporation 2201 Interest of corporation controlled by you
Shanghai Microport Limited 2101 Beneficial owner
China International Capital Corporation Limited 2201 Interest of corporation controlled by you
Cicc Capital Management Co., Ltd. 2201 Interest of corporation controlled by you
Cicc Kangrui I (ningbo) Equity Investment Limited Partners (limited Partnership) 2101 Beneficial owner
Cicc Kangzhi (ningbo) Equity Investment Management Co., Ltd. 2201 Interest of corporation controlled by you

MicroPort CardioFlow Medtech (HKSE:02160) Headlines

No Headlines